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ASSESSMENT OF DISCLOSURE IN 
EUROPEAN PRODRUG PATENT CLAIMS 
MARI MINN PHD, LLM 
ABSTRACT 
The article discusses the concept of disclosure in European patent 
applications involving prodrugs and active metabolites thereof. The article 
begins with an introduction to the scientific aspects of prodrug design to 
understand their meaning and difference from common drugs. It is followed 
by legal analysis discussing the notion of “disclosure” as an element of 
assessing novelty and inventive step. The article argues that the “disclosure” 
should be broken off into scientific disclosure affecting novelty criteria and 
disclosure as an element of enablement to judge the inventive step. The 
arguments of the article is based on the ruling of the United Kingdom (“UK”) 
landmark case Merrell Dow Pharmaceuticals v. Norton Limited and Penn 
Pharmaceuticals that has dealt with the assessment of novelty criteria by 
separating scientific disclosure from disclosure through use. As analyzed in 
the article, novelty assessment based on the disclosure doctrine may destroy 
the novelty criteria because of scientific “gaps” that may exist in the parent 
drug leading to potential infringement by the second-generation claim. The 
article also discusses the applicability of the inventive step requirement by 
analyzing relevant case law concluding that differently from the novelty 
criteria, the later should be applied differently considering explicitly 
available information about prior art or in other words, enablement of 
disclosure. Therefore, the notion and extent of the disclosure have a versatile 
impact on the assessment of the patentability criteria depending on whether 
it targets the novelty or the inventive step requirement.  
I. THE SCIENCE BEHIND PRODRUGS 
Many of the most common medicines are not effective in treating a 
large number of patients because of the genetic makeup that is responsible 
for determining how a specific drug reacts in a human body. The common 
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drug research involving a vast quantity of drug molecules cannot provide 
targeted solutions that can overcome physiochemical, biological or other 
barriers in drug efficiency and/or toxicity. Because of the genetic makeup, 
some people metabolize drugs slowly leading to toxic accumulation of the 
drug or some people metabolize drugs too quickly which may result in 
inefficiency of the drug action in the human body. When a new chemical 
entity shows barriers or limitations about its utility, it cannot be developed 
further into a therapeutic agent. 1  During the research phase, the most 
common problem related to the development of new drugs concerns 
solubility problems. Even with the use of current computational “filters” to 
minimize this problem, 2  compounds that are active in vitro may lack 
adequate pharmacokinetic properties and/or may be difficult to formulate.3 
Striving to improve the properties of a given drug and overcome the negative 
side effects of an existing drug, prodrugs have become valuable tools for 
modern drug development. A prodrug is a pharmacologically inactive 
substance4 that must go through a chemical or enzymatic transformation to 
become effective inside the body. Thus, the therapeutic rationale behind 
prodrugs is to enhance the properties of the parent drug once metabolized in 
the body. 
According to Huttunen, prodrug strategy has been used to increase the 
selectivity of drugs for their intended target. 5  These types of drugs are 
striving to offer safer and better-targeted treatment options in modern 
medicine. Metabolites6 that are closely related to prodrugs are eventually 
formed as a result of a natural biochemical process of degrading and 
eliminating compounds. Therefore, to differentiate between prodrugs and 
metabolites, it can be said that if the pharmacological effect of a medication 
is due to the transformation of a drug into a metabolite, the medication may 
 
 1. See generally Valentino J. Stella, Prodrugs: Some Thoughts and Current Issues, 99 J. PHARM. 
SCI. 4755 (2010). 
 2. Jarkko Rautio et al., Prodrugs: Design and Clinical Applications, 7 NAT. REV. DRUG DISCOV. 
255, 255 (2008). 
 3. A study conducted with the top 200 oral drug products in Japan, Great Britain, United States, 
and Spain revealed that approximately 37 percent of drugs had solubilities of less than 0.1 mg/mL See 
Toshihide Takagi et al., A Provisional Biopharmaceutical lassification of the Top 200 Oral Drug 
Products in the United States, Great Britain, Spain, and Japan, 3 MOL. PHARM. 631, 635 (2006). 
 4. The prodrug itself is often biologically inactive but may also possess biological activity—
serving as a drug itself. 
 5. Kristiina M. Huttunen et al., Prodrugs – from Serendipity to Rational Design, 63 
PHARMACOLOGICAL REVIEWS, 750, 751 (2011). 
 6. Edward D. Harris, Biochemical Facts behind the Definition and Properties of Metabolites, 
https://www.fda.gov/ohrms/dockets/ac/03/briefing/3942b1_08_Harris%20Paper.pdf (last visited Mar. 
18, 2019). 
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be called “a drug” and an “active metabolite”.7 If, on the other hand, the said 
effect is due to the release of the drug from a larger chemical entity, then the 
medication is called “drug” and “prodrug.” 
Prodrugs can masked forms of active drugs that are designed to be 
activated after an enzymatic or chemical reaction once they are into the 
body.8 Considering that during the R&D process of the parent drug it is not 
always possible to foresee all its properties, prodrugs as second-generation 
products seek to modify some of the shortcomings of the parent drug 
pertaining to absorption, distribution or metabolism. The active metabolite 
that is eventually responsible for the drug’s in vivo pharmacological effect 
differs structurally from the existing prodrug that is administered to the 
patient. 9  A small structural modification, however, may result in major 
differences in biological activity.10 Thus, second generation products can not 
only serve as a more efficient treatment option but also provide a high return 
on investment for a pharmaceutical company. The development of medicine 
using an active ingredient, the safety, and efficacy of which have already 
been established, is normally less time consuming, less expensive, and less 
risky than using a compound about which little is known.11 
From the intellectual property law perspective, it is important to 
consider that prodrugs are inactive derivatives of drug molecules that were 
already contained in the parent drug that is developed to overcome 
therapeutic barriers in drug delivery. It means that in most cases prodrugs 
are simple chemical derivatives that are only one or two chemical or 
enzymatic steps away from the active parent drug as it incorporates an active 
molecular entity within another molecular structure. To illustrate this, 
according to a study, 49 percent of all prodrugs are targeted at the formation 
of esters, which means that they are structurally like the parent drug.12 Some 
of the recently approved prodrugs include a very controversial Sofosbuvir 
that is challenged by the European Patent Office (“EPO”).  
 
 7. HYEWON AHN, SECOND GENERATION PATENTS IN PHARMACEUTICAL INNOVATION, 19 MIPLC 
STUDIES  47-49 (2014). 
 8. See generally, Peter Ettmayer et al., Lessons Learned From Marketed and Investigational 
Prodrugs, 47 J. MED. CHEM. 2393, 2394 (2004); See generally Valentino J. Stella, Prodrugs: Some 
thoughts and current issues, 99 J. PHARM. SCI., 4755, (2010). 
 9. See generally Ralph Minderop et al., Prodrugs and Metabolites – In the Twilight Zone of 
Patentability?, 2 IP IN THE LIFE SCIENCES INDUSTRIES 9, (2013). 
 10. Case T 0939/92, Triazoles (1995). 
 11. Nat’l Inst. for Health Care Mgmt., Changing Patterns of Pharmaceutical Innovation (2002), 
http://nihcm.org/pdf/innovations.pdf. 
 12. Jarkko Rautio et al., Prodrugs: Design and Clinical Applications, 7 NATURE REVIEWS 255, 256 
(2008).   
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From a legal point of view, prodrugs may offer a valuable opportunity 
to extend the life cycle of the parent drug. It is estimated that prodrugs 
account for 5-10 percent of the overall global drug market.13 Most patents 
targeting prodrugs are related to oncological research although the range of 
truly innovative drugs is, according to the same study, not more than 5-10 
percent, which suggests that many of these patents are small improvements 
or adjustments of currently existing drugs. 
Considering that prodrugs are mainly applied for as secondary patents, 
they can add 6.3 additional years to the product life cycle.14 According to 
Kapczynski, depending on the category of independent secondary patents, 
formulation patents when applied as secondary independent claims add 
approximately 6.5 years of patent life, secondary independent claims for 
salts, polymorphs, esters, etc., add 6.3 years and independently claimed a 
method of use claims add 7.4 years. 15  According to the European 
Pharmaceutical Sector Inquiry executed by the European Commission, 
applications on second generation patents for bestselling medicines is a 
common strategy to evergreen product lifecycle. The number of second 
generation patents rises significantly at the end of basic patents. 16  The 
Inquiry found that in 40 percent of cases first-generation patents are followed 
by second-generation patents and the average time before the launching of 
the second-generation patent was estimated to take place 1.5 years before the 
expiry of the basic patent. 17  Kapczynski has observed that independent 
secondary patents are not obtained randomly but rather the propensity to 
obtain secondary patents increases after successful sales suggesting they 
reflect deliberate attempts by branded firms to lengthen their monopoly for 
more lucrative drugs.18 The EC Pharmaceutical Inquiry Report revealed a 
primary to a secondary patent ratio of 1:7 meaning that the number of 
secondary patents is much higher in comparison to initial patents obtained in 
 
 13. Jarkko Rautio et al., Prodrugs – Recent Approvals and a Glimpse of the Pipeline, 109 EUR. J. 
PHARMACEUTICAL SCI. 109, 146–61 (2017). 
 14. Amy Kapczynski et al., Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis 
of “‘Secondary” Pharmaceutical Patents, 7 PLOS ONE 49470(2012), 
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0049470. 
 15. Id. 
  16. EUROPEAN COMM’N, PHARMACEUTICAL SECTOR INQUIRY REPORT (2009), 
http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/staff_working_paper_part1.pdf. 
 17. Id. 
 18. Amy Kapczynski et al., Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis 
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the beginning of drug lifecycle. 19  The interesting aspect of second-
generation patents is that most studies analyze and estimate the effects of 
patenting strategies based on calculations related to the filing date of first-
generation patents20 thus, ignoring the potential effects of second-generation 
filings to the patent portfolio lifetime. If secondary patents are frequently 
obtained later in the invention cycle then chemical compound patents, this 
will underestimate patent life, perhaps substantially.21 
Considering that a prodrug is structurally similar to its parent drug, two 
questions arise regarding patentability standards of these drugs. The first 
question that arises is the extent of disclosure or free use after the expiry of 
the parent drug in case a prodrug is claimed later during the life cycle 
process. The second question, connected to the first, is the validity of the 
prodrug patent in the light of fulfillment of the novelty and inventive step 
requirements. This article provides insight into these problems in the 
following sections and discusses the normative uncertainties by analyzing 
the most relevant case law. 
II. THE IMPACT OF DISCLOSURE IN FIRST-GENERATION CLAIMS TO 
PRODRUG PATENT APPLICATIONS 
Based on the data retrieved from the European Patent Register, it seems 
that most patents for prodrugs are claimed as second-generation patents. 
There can be several reasons that could explain it. It is possible that, at the 
time of filing the first-generation claim, potential shortcomings of the parent 
drug were not known which later caused the filing of the second-generation 
claim. It is also possible that the shortcomings in the first-generation drug 
were actually known already during the first filing, but the second-generation 
patent was later used as part of product life cycle management. 
It is a fundamental principle of patent practices that after the expiry of 
the basic patent the subject matter falls in the public domain meaning that it 
becomes accessible to anyone without having to worry about the 
infringement. When the subject matter falls in public domain, no further 
patent should be granted to the same subject matter; otherwise it would lead 
to double patenting. If anyone attempted to craft a patent application 
covering the earlier subject matter, under the assumption that the earlier 
 
 19. EUROPEAN COMM’N, PHARMACEUTICAL SECTOR INQUIRY REPORT (2009), 
http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/staff_working_paper_part1.pdf. 
 20. See generally Henry G. Grabowski & John M. Vernon, Effective Patent Life in 
Pharmaceuticals, 19 INT’L. J. TECH. MGMT. 98 (2000). 
 21. See generally C. Scott Hemphill & Bhaven N. Sampat, When Do Generics Challenge Drug 
Patents?, 8 J. EMPIRICAL LEGAL STUD. 613 (2011). 
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disclosure was complete and enabling enough, it would destroy the novelty 
and/or the inventive step requirement. However, considering that prodrug 
applications are line extensions of the parent drug, there are a few aspects to 
consider. 
For a new claim to be patent eligible, a complete and enabling 
disclosure is required which is then assessed from the practical point of view. 
This means that the disclosure of the claim should be complete enough to 
enable a person skilled in the art to perform the invention without undue 
burden. Article 84 of the European Patent Convention (“EPC”) states the 
following: “The claims shall define the matter for which protection is sought. 
They shall be clear and concise and be supported by the description.”22 In 
its case law, the EPO has clarified that Article 84 of the EPC requires that 
the claims define the subject matter for which patent protection is sought. It 
signifies that the disclosure should specify all the essential features needed 
to define the invention and that the meaning of these features should be clear 
for the person skilled in the art from the wording of the claim.23 Based on the 
EPO Board’s interpretation in case T 409/91, the underlying purpose of 
Article 83, directed to the disclosure of the invention, is the same as is stated 
in Article 84 of the EPC, Namely, to secure the grant of the proper breadth 
of patent exclusivity that can be justified by the technical contribution to the 
art. 24  The well-established jurisprudence of the EPO in respect to the 
interpretation of Article 84 of the EPC, requires that to be patentable, an 
independent claim must recite all the essential features which are necessary 
for clearly and completely defining a particular invention.25 Therefore, the 
claim should define the subject matter by reference to all its essential 
technical features. 26  Although the disclosure must contain sufficient 
information for the skilled person to perform the invention, there is no 
requirement that the inventor should have full scientific understanding 
behind the invention. In many situations, it is not possible to add the full 
disclosure in the patent application, especially in the case of biotechnological 
patents and pharmaceutical patents, as it is not possible to delimit the 
invention. From the legal point, the reason why it is relevant to differentiate 
between the scientific disclosure and practical (enabling) disclosure is that it 
 
 22. See Convention on the Grant of European Patents art. 84, Oct. 5, 1973, 1065 U.N.T.S. 199 
[hereinafter European Patent Convention]. 
 23. Case G 0001/04, Diagnostic Methods, OJ EPO 2006, ¶ 6.2.4.  
 24. Case T 0409/91, Fuel Oils, OJ EPO 1994,  3.5. 
 25. Case G 0001/04, Diagnostic Methods, OJ EPO 2006, ¶ 6.2.4. 
       26. Case G 0001/04, Diagnostic Methods, OJ EPO 2006, ¶ 6.2.. 
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defines the extent of the subject matter for which protection is sought and 
how it reflects the evaluation of novelty and the inventive step requirements. 
It is especially relevant for patents involving prodrugs as a small piece of 
scientific information in the disclosure to determine the perspective for 
patentability. 
According to Article 83 of the EPC, the claim must also contain 
sufficient technical disclosure of the solution to the problem. 27  EPO 
Guidelines for Examination clarify that a detailed description of at least one 
way of carrying out the invention must be given. Therefore, the description 
should disclose any essential feature for carrying out the invention by the 
person skilled. When the first-generation patent is claimed for the parent 
drug, the disclosure should include a number of examples, alternative 
embodiments or variations of the subject matter extending over the area 
protected by the claim.28 
In its case T-0409/91 the EPO Boards of Appeal has held that “The 
essential features of the invention, which must be used for defining the 
matter for which protection is sought, in accordance with Art. 84 EPC in 
combination with Rule 29(1) and (3), are all those technical features which 
are necessary to define an invention which is patentable under the EPC, 
including any feature which is necessary to define matter which also meets 
the requirement of sufficient disclosure pursuant to Article 83.”29 
Defining the essential features in the first-generation patent has an 
impact on the assessment of novelty in the second-generation patent 
application. The scientific disclosure is in direct conflict with the novelty 
criteria but according to Art. 54 of the EPC, novelty is judged based on the 
information made available at the time of the application. The novelty is thus 
judged by the (scientific) knowledge available. The inventive step 
requirement, on the other hand, refers to the enabling aspect of the invention 
to be carried out by the person skilled in the art. or these reasons, the extent 
of disclosure should be analyzed from two different angles, the scientific 
disclosure, which is connected to the novelty, and the enabling aspect of the 
disclosure, which is connected to the inventive step. 
 
 27. See European Patent Convention, supra note 22, art. 83.  
 28. European Patent Office, Guidelines for Examination, pt. F, ch. III, § 1 (2018), 
https://www.epo.org/law-practice/legal-texts/html/guidelines/e/f_iii_1.htm. 
 29.  Case T 198/84, Hoechst ex parte, OJ EPO  (1985). In the EPO Case T 292/85 it was stated that 
in certain cases a description of one way of performing the claimed invention might be sufficient to 
support broad claims with functionally defined features. For example, where the disclosure of a new 
technique constitutes the essence of the invention and the description of one way of carrying out the 
invention enables the person skilled in the art to obtain the same effect of the invention in a broad area 
by use of suitable variants of the component features. See Case T 0292/85, Genentech, OJ EPO (1988). 
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In the case of prodrugs, although being structurally similar to the parent 
drug, the main challenge does not arise from the scientific disclosure because 
these types of inactive derivatives of original drugs usually contain improved 
scientific knowledge. The inability to guarantee a patent for prodrugs stems 
rather from the inability to come to terms with the practical aspect of the 
disclosure because it raises questions whether a person skilled in the art was 
expected to reach to a specific result already during the assessment of the 
first-generation claim or not. Differently from prodrugs, the active 
metabolites that are the molecules (end products) of a drug (or prodrug) are 
generally considered as being already included in the first-generation claim 
in Europe from both the scientific, as well as practical, point of view their 
“behavior” during metabolism is a natural consequence, therefore they are 
excluded from patentability. As a consequence, they do not fulfill even the 
novelty requirement. 
Still, under some circumstances, the scope of the patent is not limited 
to the version that the inventor invented, but could cover the subsequently 
modified versions if each falls within the scope.30 It can be deduced that the 
inventor is not expected to include a “complete” scientific disclosure in the 
patent application, but should provide sufficient information to the examiner 
to carry out the invention. For some types of inventions, it can mean that the 
disclosure, although sufficient from the practical point of view, may contain 
“gaps” from the scientific aspect regarding any of its specific elements. 
These elements, on the other hand, can themselves be patentable subject 
matter, or may already be encompassed in the disclosure without being 
directly referred. For example, prodrugs and especially metabolites thereof 
can be viewed as anticipated inventions although they may not have been 
previously disclosed in the parent claim. At the same time, prodrugs can be 
viewed as a separate subject matter eligible for a new patent. The polemics 
here is whether these second-generation prodrug claims should 
automatically be refused to avoid a situation where the subject matter of the 
first claim is indirectly encompassed in the second-generation claim or find 
the prodrug patent valid which could mean that the first-generation invention 
is delayed before entering the public domain. The extent of disclosure and 
its effects on the novelty and inventive step requirements will be dealt with 
in the following sections of this article. 
 
 30. Changing Patterns of Pharmaceutical Innovation, supra note 11, at 19. 
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III. ASSESSMENT OF NOVELTY – THE MERRELL DOW CASE 
Prodrugs are chemically modified versions of the pharmacologically 
active agent that must transform in vivo to release the active drug. 31 
Considering that claims involving prodrugs usually refer to minor 
modifications of the structure or the chemical makeup of a molecule 32 
meaning that they are only a few steps away from the parent drug, the main 
challenge for patenting prodrugs as product related second-generation claims 
comes from potential structural similarities to the parent drug of the first-
generation claim. In other words, potential challenges arise from destroying 
the novelty and/or inventive step requirements of Articles 54 and 56 of the 
EPC. Article 54 requires that “for the invention to be considered novel, it 
should not form part of the state of the art.”33 If the concept of an invention 
is completely disclosed within a single piece of prior art, it lacks novelty, 
regardless of whether it was independently developed from the earlier 
invention.34 Thus, the novelty connects to the availability of already existing 
information on prior art and the anticipation thereof. In case the invention is 
already claimed in an earlier (first generation) invention, the prior disclosure 
enables the entire claimed invention in addition to disclosing each and every 
element of the invention. 35  According to John F. Duffy, 36  whether the 
disclosure forms part of the state of the art depends whether there is a natural 
result, meaning that it should be decided whether the later invention is the 
natural result flowing explicitly from the earlier disclosure. What has to be 
established in the examination as to novelty is whether the state of the art is 
such as to make the subject matter of the invention available to the skilled 
person in a technical teaching.37 
In the case of prodrugs and active metabolites, the question that arises 
is how to judge the extent of the scientific disclosure because this type of 
second-generation inventions may already have been disclosed in the first 
application without being disclosed. In other words, the question is how to 
 
 31. Id. at 2.   
 32. Case T 198/84, Hoechst ex parte, OJ EPO (1985) at 2–3. 
 33. See European Patent Convention, supra note 22, art. 54.  
 34. Stephen M. Mauer & Suzanne Scotchmer, The Independent-Invention Défense in Intellectual 
Property, 69 ECONOMICA 535–47 (2002). 
 35. Synthon BV v. SmithKline Beecham plc [2005] H.L. 59, at ¶14. 
 36. See generally John F. Duffy, Rules and Standards on the Forefront of Patentability, 51 WM. & 
MARY L. REV. 638, (2009). 
 37. Case T 198/84, ¶ 6, A generic disclosure does not destroy the novelty of any of the specific 
possibilities falling within the disclosure unless it claims a specific generic feature that encompasses the 
latter. 
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define the extent of the disclosure for the assessment of novelty in the case 
of prodrugs and metabolites thereof if they fall within a scientific “gap.” This 
means that although they are not explicitly disclosed in the first-generation 
application, they are nevertheless anticipated even when the inventor had no 
knowledge about such an effect. 
What has to be established in the examination as to novelty is whether 
the state of the art is such as to make the subject matter of the invention 
available to the skilled person in a technical teaching.38 However, different 
from the evaluation over the inventive step is that compared and analyzed to 
the existing technical criteria, novelty is evaluated not on what it adds to the 
existing technical teaching, but whether it can be considered a new invention 
overall. In other words, it is whether the subject matter of the invention is 
available to the person skilled in the art in technical teaching, which thus 
should be an absolute novelty, not a natural result of the existing disclosure.39 
Differently, from assessing the inventive step, it is not the newly discovered 
effect that is evaluated for novelty, but the new disclosure has to form a new 
invention per se. For assessing novelty of second-generation claims, it is not 
important whether there is a technical effect present over the prior art as this 
is evaluated at the stage of analyzing the existence of the inventive step. 
However, what is important about the technical teaching in the context of 
novelty is that the second-generation patent should not disclose a teaching 
that is anticipated by the examiner as a “natural result” of the first-generation 
claim. 
When the first-generation claim covering the parent drug already 
included a possible (future) prodrug derivative, the novelty criteria in the 
second-generation claim could not be met. The teaching of the prior art is 
not confined to the detailed information given in the examples of how the 
invention is carried out40 but relies on the information available in the claims 
and the description of the application that becomes the starting point for the 
person skilled in the art to carry out the invention and test novelty. For this 
reason, according to the established EPO case law,  
 
In the case of one of a number of chemical substances described by its 
structural formula in a prior publication, that substance’s particular 
stereospecific configuration (thereof form) - though not explicitly 
 
 38. Id. at ¶ 6.  
 39. The new disclosure should not be a mere embodiment of the prior disclosure but is expected to 
form another invention. See Case T 0279/89, In re Texaco Dev. Corp., OJ EPO (1991) ¶ 4.1.   
 40. Case T 0012/81, In re Bayer AG, OJ EPO (1982). 
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mentioned - is anticipated if it proves to be the inevitable but undetected 
result of one of a number of processes adequately described in the prior 
publication by indication of the starting compound and the process.41  
 
Thus, when deducting this reasoning to prodrugs, if the second-generation 
family of the compound partially already covered what was disclosed in the 
first-generation disclosure, novelty cannot be approved. But at the same 
time, “if the (second-generation) subject matter is a defined compound, 
whereas the prior art discloses a family of [a] compound defined only by a 
general formula covering the defined compound, but not describing it 
explicitly, the invention must be considered novel.”42 
 Deducing from the EPO case law, the second-generation claim may 
nevertheless fall within the scope of the parent claim, even if it was not 
explicitly described as the disclosure of the parent claim that could already 
anticipate the subject matter of the other claim due to the scientific “gap” or, 
in other words, explicit anticipation. Therefore, the success of the second-
generation patent application relies on available knowledge, the extent of 
disclosure, and the wording of the patent application concerning what is 
claimed. 
The validity of prodrug and metabolite patents in Europe has been dealt 
with in the landmark case Merrell Dow v. H.N. Norton & Co. Ltd. in the 
UK43. The case concerned a metabolite of Terfenadine, which was a line 
extension of the original drug patented in the 1970s. Considering that the 
second-generation patent involving a metabolite was patented a decade later, 
a generic drug company Norton challenged the metabolite patent as a de 
facto extension of the original drug based on validity and/or infringement. 
The case was under discussion in the U.S., Germany and the UK. In the first 
two countries, the main challenge was about patent infringement whereas the 
litigation brought up in the UK was the only country challenging the validity 
of metabolite claims. Therefore, the questions regarding novelty and 
inventive step arose in the context of challenging patent validity. Generally, 
 
 41. See supra, Section II.   
 42. The Board stated the following: “If a mere precisely structurally defined (described by a 
chemical reaction) class of chemical compounds with only one generically defined substituent does not 
represent a prior disclosure of all the theoretical compounds encompassed by an arbitrary choice of a 
substituent definition, it must be clearly valid for a group of chemical substances, the general formula of 
which has two variable groups. Therefore, in the present case, a class of chemical compounds, defined 
only by a general structural formula having at least two variable groups does not specifically disclose 
each of the individual compounds which would result from the combination of all possible variants within 
such groups.” Case T 0007/86,  DRACO v. Napp Labs. Ltd., OJ EPO (1987)  ¶ 5.1. 
 43. Merrell Dow Pharms. Inc v. Norton & Co. Ltd., [1996] 3 RPC 76 , 87 (H.L.). 
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for a patent in the second-generation application to be held invalid for the 
lack of novelty, the prior art should disclose the same invention. In Merrell 
Dow, Lord Hoffmann invalidated the patent for having been anticipated by 
disclosure.44 The notion and extent of the disclosure were addressed in detail. 
Referring to Art. 54 of the EPC, it was found that what constitutes 
anticipation is not simply something that was done before.45 To determine 
the extent of the disclosure and consequently, judge novelty, it should be 
clarified what constitutes prior art in terms of “use” and (scientific) and 
“disclosure.” Lord Hoffmann made a distinction between these terms as he 
considered that for the prior art to have a destructive impact on the 
assessment of novelty through use required that the information should have 
been made public through its use which, in this specific case, was not an 
issue. Instead, the judge found that the disclosure does not mean everything 
made available to the public in a written form or by public statement. The 
view was the disclosure by itself can contain information without being made 
public through use, meaning that the result of the metabolite action in the 
human body was due to the scientific disclosure (which was not, at the time, 
known to the inventor) rather than due to the communication to the public 
through its use. Thus, the second-generation invention should be anticipated 
based on the (scientific) disclosure that enables a person skilled in the art to 
convey sufficient information to work the invention.46 This means that the 
anticipation by “use” has a different basis than anticipation by (scientific) 
“disclosure”. 
For purposes of clarifying the difference between these terms, Lord 
Hoffmann stated the following referring to the CPC/Flour Concentrate 
case47: 
if the recipe which inevitably produces the substance is part of the state of 
the art, so is the substance as made by the recipe. The prior inventor must 
be clearly shown to have planted his flag at the precise destination before 
the patentee.48 
 
It seems what the judge had in mind is that when the subsequent 
invention was performed based on the disclosure, it would necessarily have 
led to the infringement of the initial patent. Thus, the outcomes of performing 
 
 44. Merrell Dow Pharms. Inc v. Norton & Co. Ltd., [1996] 3 RPC 76 , 87 (H.L.). 
 45. Id. at 84. 
 46. Id. at 34 
 47. Id. 
 48. Id. at 90. 
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the second-generation invention should not be one of the possible options or 
result, but it should be based on the information disclosed even when it was 
not explicitly described in the patent. It should be anticipated. If it is one of 
the possible consequences, one cannot say that performing this invention 
would infringe.49 This statement is supported by Union Carbide Corporation 
v. Basf AG, Dow Chemical Co. and NV DSM. Here, the EPO Boards of 
Appeal concluded that: 
 
“[i]t may be easy, given a knowledge of a later invention, to select from 
the general teachings of a prior art document certain conditions, and apply 
them to an example in that document, so as to produce an end result having 
all the features of the later claim. However, success in so doing does not 
prove that the result was inevitable. All that it demonstrates is that, given 
knowledge of the later invention, the earlier teaching is capable of being 
adapted to give the same result. Such an adaptation cannot be used to 
attack the novelty of a later patent.”50 
 
In the case of metabolites that make an effect on the molecular level as 
the end products after being metabolized, it is expected that when performing 
the first-generation invention involving a drug it would necessarily result in 
the same effects as the second-generation metabolites do. Therefore, the 
result should be expected in the first-generation patent. Also, as discussed in 
Merrell Dow, the (scientific) disclosure that sets the basis for the evaluation 
of novelty may not be known to the inventor himself51 Nevertheless, it does 
not make the following claim valid. What matters is the disclosure must 
necessarily result in an infringing invention in the second-generation claim 
once performed. This is what sets novelty apart from the practical 
enablement or in other words, inventive step requirement. In Merrell Dow, 
the ingestion of terfenadine by hay-fever sufferers, which was the subject of 
prior disclosure, necessarily entailed the making of the patented acid 
metabolite in their livers. 52  It was, therefore, an anticipation of the acid 
metabolite, even though no one was aware that it was being made or even 
that it existed. A similar view regarding the assessment of novelty in light of 
judging the extent of disclosure was seen in Synthon v. SmithKline Beecham 
in the UK, which contested a patent for a crystalline form of paroxetine 
 
 49. Lord Hoffmann said, “. . . the prior disclosure must be construed as it would have been 
understood by the skilled person at the date of the disclosure and not in the light of the subsequent patent.” 
Id. at 84. 
 50. Case T 0396/89, Union Carbide Corp. v. BASF Aktiengesellschaft et al., OJ EPO (1991) ¶ 4.4  
 51. Synthon BV v. SmithKline Beecham plc [2005] H.L. 59, at 23. 
 52. Id. at 23.  
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Methosulfate. 53  In Synthon, the judge sought to separate the notion of 
disclosure from enablement since disclosure concerns novelty and 
enablement concerns the obviousness/inventive step.54 
As for assessing the novelty criteria in the light of prior disclosure, the 
judge came to a similar conclusion as in Merrell Dow. The judge concluded 
that relying on prior art should disclose the subject matter in a manner that, 
if performed, it would necessarily result in patent infringement.55 Based on 
these judgments, it can be concluded that for the assessment of novelty 
concerning prodrugs and/or active metabolites the main doubt concerns the 
extent of the scientific disclosure within the first-generation claim. In 
evaluating disclosure, it does not matter whether the second-generation 
subject matter was explicitly mentioned in the parent claim because, from 
the scientific point of view, this type of subject matter is anticipated. The 
existence and advantages of the second-generation subject matter are 
generally, in this situation, disclosed because carrying out the invention 
would inevitably lead to the production of the second-generation product by 
the person skilled in the art. Although the concept of the invention is not 
completely disclosed in the first claim, if the subject matter of the second-
generation claim would fall within the scientific “gap” disclosed in the parent 
drug, the result would inevitably lead to the construction and or effects of the 
prodrug/metabolite claim. The Court interpreted the novelty provision to 
find that the earlier patent had put information about the Terfenadine 
metabolite into the public domain, despite not publicly teaching the ‘missing 
element’ in the patent specification.56 The findings and reasoning of the 
decision in Merrell Dow are well-suited for justifying the inexistence of 
novelty in the following patent application to avoid evergreening attempts as 
part of drug life cycle management. Certainly, each case is judged based on 
its contents, but the UK judgment has followed the same approach denying 
metabolite patents in Europe as did the EPO. However, prodrugs are still 
patentable subject matter in Europe as they are in the UK, but the passing of 
the novelty test based on the contents of the disclosure depends on the 
wording of a claim and the extent of the scientific disclosure. The following 
section of the article discusses the understanding of disclosure within the 
 
 53. Id. at 23. 
 54. Id. at 66. 
 55. Id. at 22. 
 56. See generally H. Samuel Frost, The Unique Problem of Inventions which are Fully Enabled and 
Fully Described but not Fully Understood(Merrell Dow’s Terfenadine Revisited), 15 INTELL. PROP. J. 
2,(2007). 
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notion of enablement as a means of assessing the inventive step in prodrug 
and metabolite patent applications in Europe. 
IV. DISCLOSURE AS AN ELEMENT OF ENABLEMENT FOR ASSESSING THE 
INVENTIVE STEP 
It has been an accepted legal principle that the extent of the patent 
monopoly should correspond to and be justified by the technical contribution 
to the state of art.57 Therefore, the extent to which an invention is sufficiently 
disclosed as an element of enablement is highly relevant for the evaluation 
of second-generation patent applications. The inventive step requirement is 
considered the “final gatekeeper of the patent system.”58 This means that 
even if relatively trivial changes to the prior art could survive the novelty 
and industrial applicability requirements, the inventive step will function as 
the ultimate requirement and filter the patentable from the unpatentable.59 
The relevance of the inventive step requirement is to guarantee there is a 
technical advancement in the teaching in comparison to the state of the art. 
It should not be an extension or incremental development of technology,60 
which may pass the novelty check but would add nothing to the level of 
technological advancement. 
The inventive step can only be assessed when the invention is deemed 
novel. In comparison to the novelty, the inventive step seems to have higher 
standards of applicability. Art. 56 of the EPC defines the inventive step in 
the following manner: “An invention shall be considered as involving an 
inventive step if, having regard to the state of the art, it is not obvious to a 
person skilled in the art.”61 While both of these definitions deal with the state 
of art the novelty criteria is informative. To pass the evaluation, the main 
factor considered is the available information of prior art as discussed in the 
previous section. Novelty is judged based on the scientific disclosure, which 
may mean that this information can fall in the scientific “gap,” which 
nevertheless can destroy novelty. The inventive step requirement, on the 
other hand, refers to the technical teaching, which means in addition to being 
novel to the examiner, the invention should contain a new technical 
 
 57. Case T 0409/91, In re Exxon Chem. Patents, Inc., (1993) at 3.3 (Eur. Pat. Bd. of App.). 
 58. R. P. MERGES & J. F. DUFFY, PATENT LAW AND POLICY: CASES AND MATERIALS 619–20 
(LexisNexis, 5th ed. 2011).  
 59. Id. at 620. 
 60. Mark F. Grady & Jay L. Alexander, Patent Law and Rent Dissipation, 78 VA. L. REV. 305, 340 
(1992). 
 61. See European Patent Convention, supra note 22, art. 56. 
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contribution to the state of the art. While the novelty requirement puts the 
examiner in a passive state,62 the inventive step requirement has the opposite 
effect as it requires the active participation of the person skilled in the art to 
perform tests and make the ultimate evaluation. The inventive step requires 
that the invention, based on the prior art, is not obvious to the examiner. For 
assessing the inventive step, the problem-solution approach is used. This 
means that the second-generation claim should provide a technical problem 
over the prior art that needs to be “solved” to see whether the solution can 
be considered inventive (non-obvious) in comparison to the existing 
knowledge. 63  Thus, an unexpected advantage that could not have been 
predicted from the prior art is taken as evidence of an inventive step. In this 
light, for the fulfillment of the inventive step requirement, the newly claimed 
compound/molecule should present a special technical property that is not 
previously disclosed. It means that the second-generation claim should offer 
a “surprising” technical effect to the existing prior art. In the case of 
prodrugs, it can be either a new property or a better activity in comparison 
to the existing invention. 
In the case of chemical inventions concerning potential structural 
similarity, the EPO has taken the view64 that “to deny the patent for the lack 
of the inventive step, a skilled person should be expected to find the same or 
similar usefulness in comparison to the known compound as means of 
overcoming the technical problem.” What makes the difference is the range 
of structural differences of the second-generation drug when compared to the 
parent compound. If these differences are lacking or very small, they would 
have an insignificant bearing on those properties that are essential for solving 
the technical problem at issue. Because of structural similarities with the 
parent drug, the inventive step for a prodrug often turns on the structural 
similarities and differences between the claimed compound and prior art.65 
In T 2402/10 the board stated “in the field of drug design any structural 
modification of a pharmacologically active compound is, in the absence of 
an established correlation between structural features and activity, a priori 
 
 62. Id.; Frost, supra note 56, at 19. 
 63. In assessing the inventive step, the EPO has applied the following three-step test: “1. 
Determining the ‘closest prior art’; 2. Establishing the ‘objective technical problem’ to be solved; and 3. 
Considering whether or not the claimed invention, starting from the closest prior art and the objective 
technical problem, would have been obvious to the skilled person.” See Implementing Regulations – to 
the Convention on the Grant of European Patents of 5 October 1973.  
 64. Case T 0358/04, Retroviral protease inhibitors/G.D. SEARLE, OJ EPO (2006) ¶ 4.5.3 . 
 65. JARKKO RAUTIO, PRODRUGS AND TARGETED DELIVERY: TOWARDS BETTER ADME 
PROPERTIES 73 (Wiley 2011).  
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expected to disturb the pharmacological activity profile of the initial 
structure.”66 In the case of prodrugs, the structural similarities in the first- 
and second-generation claims can otherwise lead to double patenting if the 
inventive step is not approached with caution. Double patenting can be raised 
where the subject matter of the granted invention is encompassed by the 
claim later put forward.67 However, what makes the difference whether the 
inventive step stage is passed successfully or not is whether the second-
generation claim has  distinguishing features  in comparison to  the first-
generation claim. Under this condition, the subject matter of the second-
generation claim and the first-generation claim cannot be considered as “the 
same subject matter. Thus, the evaluation of the inventive step has stricter 
standards in Europe when compared to the assessment of the novelty criteria. 
The inventive step has to occur for the entire selection range, but the novelty 
criteria is fulfilled when the claimed subject matter is distinguished from the 
prior art in the range of overlap by a new technical element.68 
As discussed in the previous section, to destroy novelty, the disclosure 
must infringe the invention If the performance of an invention would make 
the second-generation subject-matter obvious to the person skilled in the art 
but not necessarily infringe the first one, then one can discuss the practical 
enablement in judging the inventive step, not novelty.69 Therefore, while 
Merrell Dow divided the destruction of novelty into two categories, namely 
disclosure by use and scientific disclosure, the inventive step requirement is 
connected to the practical enablement of the disclosure. Enablement means 
that a person skilled in the art should be able to perform the invention, which 
satisfies the requirement of disclosure.70 Thus, the inventive step can be 
judged based on what is previously disclosed, meaning that for the 
destruction of the inventive step, either the prior disclosure of the invention 
or general common knowledge would have enabled a person skilled in the 
art to make it.71 The inventive step depends on what is disclosed in the prior 
art making it different from novelty, which may be judged, based on Merrell 
Dow, also on the “missing” information (the scientific “gap”) in the 
disclosure made available. 
In Union/Carbide, the EPO Boards of Appeal clarified that:  
 
 
 66. Case T 2402/10, Prostaglandin derivatives / Pfizer, OJ EPO (2012). 
 67. Case T 0307/03, ARCO/Double patenting, [2007] (Eur. Tech. Bd. of App.). 
 68. Case T 0012/90, Bayer AG, OJ EPO (1990). 
 69. Id.; Synthon BV v. SmithKline Beecham plc [2005] H.L. 59, at 49.  
 70. Id.; Case T 0396/89, Union Carbide Corp. v. BASF Aktiengesellschaft et al., OJ EPO (1991). 
 71. Asahi Kasei Kogyo KK’s Application [1991] RPC 485 (HL). 
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It may be easy, given a knowledge of a later invention, to select from the 
general teachings of a prior art document certain conditions, and apply 
them to an example in that document, so as to produce an end result having 
all the features of the later claim. However, success in so doing does not 
prove that the result was inevitable. All that it demonstrates is that, given 
knowledge of the later invention, the earlier teaching is capable of being 
adapted to give the same result. Such an adaptation cannot be used to 
attack the novelty of a later patent.72  
 
If the disclosure of prior art would make it obvious to the skilled person how 
to adapt the invention in a manner that could eventually result in 
infringement, one can challenge the inventive step but not novelty because 
the infringement would be based on the existing available information of 
prior art. Secondly, enablement would not mean an automatic and inevitable 
infringement, but it is one of the possibilities that may lead to such 
infringement if adaptions are made. In other words, enablement means that 
for the destruction of the inventive step, the skilled person is expected to 
perform the invention, which satisfies the requirements of disclosure. Based 
on Hill v. Evans,73 for the assessment of novelty, no further experiments with 
the subject matter are performed as it is judged based on the (scientific) 
disclosure. Given Merrell Dow, the argument in Union/Carbide and Hill v. 
Evans is different because of the case’s substantial circumstances. Namely, 
the intriguing aspect of Merrell Dow was that the second-generation 
invention disclosed in the prior art was not the same as claimed in the 
invention itself, but if performed by the examiner, it would infringe the 
claimed invention. In this case, the debate concerned whether the disclosure 
contained in the prior art enabled the examiner to make Terfenadine, not 
whether it enabled him to make metabolites. This makes judging novelty 
different from the inventive step and the questions that were raised regarding 
validity in Merrell Dow concerned novelty, not the inventive step. 
 
 72. Id.; Case T 0396/89, Union Carbide Corporation v. BASF Aktiengesellschaft et al., OJ EPO 
(1991) ¶ 4.4. 
 73. In Hill v. Evans in the UK, the House considered what would amount to disclosure of an 
invention. Lord Westbury LC said “I apprehend the principle is correctly thus expressed: the antecedent 
statement must be such that a person of ordinary knowledge of the subject would at once perceive, 
understand and be able practically to apply the discovery without the necessity of making further 
experiments and gaining further information before the invention can be made useful. If something 
remains to be ascertained which is necessary for the useful application of the discovery, that affords 
sufficient room for another valid patent.” Hill v. Evans, (1862) 31 LJ (NS) 457, 463. 
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CONCLUDING REMARKS 
Although second-generation patents are sometimes seen as lacking true 
inventiveness and, therefore, should perhaps not be granted,74 it is not always 
the case. The main concern about drug patent has been the issuing of 
secondary patents with questionable value, meaning that although a patent 
can qualify from the technical point of view for a new patent but it may not 
necessarily have any significant therapeutic value from the medical aspect. 
It has therefore been questioned whether these types of patents rather reflect 
their input and true innovative value. Lemley and Shapiro have pointed out 
that among the vast number of patents filed most of them have little value 
and such patenting leads to a situation where third parties have no 
meaningful opportunity to participate in the patent granting system. 75 
Burdon and Sloper state that “[a] key element of any lifecycle management 
strategy is to extend patent protection beyond the basic patent term for as 
long as possible by filing secondary patents, which are effective at keeping 
generics off the market.”76 According to the Pharmaceutical Sector Inquiry, 
which studied the tendencies of European pharmaceutical companies to use 
sequential patents, the primary-to-secondary patent ratio is 1:7, and 
interestingly, the ratio for pending patents is much higher in comparison to 
granted patents.77 Another study conducted in the U.S. market suggested that 
around half of pharmaceutical products are additionally covered with follow-
on patents.78 
Lemley and Shapiro79 argue that “[m]odern technologies incorporate 
not one but a number of combinations of patents for different components of 
the basic invention.” A study conducted by Stella has suggested that, in many 
cases, a look at the structure of the active drug with the additional claim of 
prodrugs suggested that prodrugs would serve minimal advantage. 80 
According to his estimation, the vast majority of prodrug patents contain 
 
 74. Id.; Asahi Kasei Kogyo KK’s Application [1991] RPC 485 (HL). 
 75. See generally Mark A. Lemley & Carl Shapiro, Probabilistic patents, 19 J. ECON. PERSP. 75 
(2005). 
 76. Michael Burdon & Kristie Sloper, The Art of Using Burden Secondary Patents to Improve 
Protection, 3 INT’L J. MED. MARKETING, 226, 266 (2003). 
 77. EUROPEAN COMM’N, PHARMACEUTICAL SECTOR INQUIRY REPORT (2009), 
http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/staff_working_paper_part1.pdf. 
 78. See generally Amy Kapczynski et al., Polymorphs and Prodrugs and Salts (Oh My!): An 
Empirical Analysis of “‘Secondary” Pharmaceutical Patents, 7 PLOS ONE 49470 (2012). 
 79. See generally Mark A. Lemley & Carl Shapiro, Patent Holdup and Royalty Stacking, 85 TEX. 
L. REV. 1992 (2007). 
 80. See generally Valentino J. Stella, Prodrugs: Some thoughts and current issues, 99 J. PHARM. 
SCI. 4755 (2010). 
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little true novelty either in the chemical or biological sense meaning that less 
than 5-10 percent of the patents represent true creativity.81 Correa has made 
a similar conclusion arguing that “[a] claim on a prodrug will generally fail 
to meet the inventive step standard unless evidence is provided that it 
overcomes pharmaceutical or pharmacokinetically based problems of the 
parent drug in a non-evident manner.”82 
Although the improved efficacy of prodrugs in overcoming the barriers 
in parent drug delivery can be disputed, the standards applicable to these bio-
reversible derivatives of drug molecules consider the technical side of 
claimed inventions. A key consideration under patent law is whether the 
development of a new prodrug is the outcome of an inventive activity or of 
routine research and experimentation. The first question that was addressed 
in these article was the extent of disclosure in second-generation patent 
applications concerning prodrugs. The second question, which is closely 
connected to the first one, is the validity of the prodrug patents in the light 
of fulfillment of novelty and inventive step requirements. To analyze these 
issues, this article provided an overview about the scientific notion of 
prodrugs and active metabolites explaining that because of structural 
similarities with the parent drug, prodrugs and active metabolites face 
challenges in overcoming the patentability criteria pertaining in the 
European Patent Convention. This article further analyzed the understanding 
of the term “disclosure” in European patent applications arguing that the 
scientific disclosure should be separated from the practical disclosure as they 
are targeted to judging different criteria of patentability. The extent of 
disclosure has a direct impact on the assessment of novelty and the inventive 
step requirements in European patent application. As analyzed in Merrell 
Dow the scientific disclosure relates to the novelty criteria. Deduced from 
the analysis in Merrell Dow, it was concluded that although novelty is 
generally assessed based on the information made available to the public, in 
cases involving subject matter targeting prodrugs and metabolites, it is 
possible that the scientific disclosure that sets the basis for the assessment of 
novelty, falls within the scientific “gap” meaning that it may not even be 
communicated to the public to be considered as prior art. Thus, although 
novelty contains the element of anticipation, one should distinguish between 
anticipation by “use” and by (scientific) “disclosure.” When this discussion 
is applied to the assessment of novelty for prodrugs and metabolite patents, 
 
 81. Id. at 4755. 
 82. Carlos M. Correa, Guidelines for Pharmaceutical Patent Applications: Examining 
Pharmaceutical Patents from Public Health Perspective, UNDP, at 10 (2015), 
https://www.undp.org/content/dam/undp/library/HIV-AIDS/UNDP_patents_final_web_2.pdf.  
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the disclosure, even if not directly stated in the application of the parent drug, 
would inevitably infringe that patent if the second invention was performed. 
Thus, the prodrug/metabolite should (from the scientific perspective) be 
expected to contain the parent drug already. 
The article also dealt with the legal analysis concerning the assessment 
of the inventive step arguing that the disclosure should be based strictly on 
the information made available the prior art. Differently, from the scientific 
disclosure that is a passive notion, the disclosure involving enablement 
requires active performance from the examiner to conduct tests with the 
subject matter. To destroy the inventive step requirement, enablement should 
be based on the information available in the prior art and the examiner should 
be capable of performing the invention as disclosed. 
